

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Non-Preferred Rapid Acting Insulin

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Comments	Quantity Limit
Admelog (insulin lispro) authorized generic insulin lispro authorized generic insulin aspart	Preferred	May be subject to quantity limit
Apidra (insulin glulisine) Fiasp (insulin aspart) Humalog (insulin lispro) Lyumjev (insulin lispro-aabc) Novolog (insulin aspart)	Non-Preferred	

APPROVAL CRITERIA

Requests for Apidra, Fiasp, Humalog, Lyumjev, or Novolog may be approved when the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to Admelog, authorized generic insulin lispro, or authorized generic insulin aspart.

Key References:

1. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes - 2019. *Diabetes Care*. 2019;42: S90-S102.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 12, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

4. Garber AJ, Abrahamson MJ, Barzilay JI, et. al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. *Endocrine Practice*. 2019;25:69-100.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
6. McCulloch DK. General principles of insulin therapy in diabetes mellitus. Last updated: September 20, 2019. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: September 28, 2019.
7. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Last updated: November 14, 2017. Available at <https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm>. Accessed: October 12, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.